GMP RNA Synthesis and Manufacturing

Self-amplifying RNAs (saRNAs) are a subclass of mRNA that can replicate to produce more copies of mRNA by co-opting the cellular machinery. saRNA vaccines in particular, are advantageous in vaccine research due to their ability to self-replicate, allowing exponential expression of antigens.

Compared to the conventional mRNA vaccination approach, saRNA can induce equivalent protection with lower doses and has also been shown to elicit longer antigen expression in vivo.

IntegrateRNA provides custom self-amplifying RNA (saRNA) synthesis, at milligram to multigram scales. Based on effective and flexible saRNA synthesis platform, our services include condon optimization, saRNA design, template preparation, in vitro transcription, purification, and quality control.

Start your project

Transfer RNAs (tRNAs) are key molecules that carry amino acids to ribosomes and decode the genetic code using anticodons to translate genetic information into the primary sequence of a polypeptide chain. In vitro synthetic tRNAs have provided new ways to study protein structure, dynamics, post-translational modifications, and cell-free protein synthesis, as well as manufacture protein-drug conjugates.

IntegrateRNA offers in vitro synthetic tRNA charged with natural amino acid or non-canonical amino acid (ncAA), including fluorescent-labeled amino acid, biotin-labeled amino acid, and functional amino acid.

Start your project

GalNAc (N-Acetylgalactosamine) is a naturally occurring sugar that binds to the asialoglycoprotein receptor (ASGPR), which is highly expressed in the membrane of hepatocytes (liver cells). Coupling GalNAc sugars to stabilized oligonucleotide molecules allows them to target liver cells and carry out their function. By decorating it to a certein delivery system as a targeting moiety, GalNAc has achieved compelling successes in the development of nucleic acid therapeutics in recent years.

IntegrateRNA provides GalNAc conjugated oligonucleotides containing a monovalent/trivalent GalNAc cluster attached to the 3'-end or 5'-end of the oligonucleotide. These conjugates are compatible with DNA, 2'-OMe, 2'-MOE, 2'F oligonucleotides including the options of phosphodiester or phosphorothioate linkages.

Start your project

Lipid nanoparticles (LNPs) are considered to be state-of-the-art technology for nucleic acid delivery. LNPs are capable of encapsulating and delivering therapeutic agents to specific locations in the body and releasing their contents at the desired time, thus providing a valuable platform for the treatment of a variety of diseases.

In order to facilitate the development of RNA therapeutics and the application of related research, IntegrateRNA is committed to developing safer and more effective RNA delivery systems for our customers around the world to improve RNA stability and enhance the ability of cells to take up and release RNA.

Start your project

The goal of high-throughput LNP formulation screening is to identify the most effective and stable LNPs that can deliver nucleic acid cargo to target cells with high efficiency and minimal toxicity. This process involves the synthesis and characterization of a large library of different LNP formulations, which can vary in lipid composition, nanoparticle size, charge, and surface modifications.

To address the screening needs in the early-stage development of LNP formulations, IntegrateRNA helps customers screen engineered LNP formulations, to ensure that they can perform the complicated series of actions necessary for effective drug delivery including transport across cell membranes and intracellular release, while keeping their therapeutic cargo intact.

Start your project